Nurix Therapeutics Inc
NRIX
Company Profile
Business description
Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.
Contact
1600 Sierra Point Parkway
BrisbaneCA94005
USAT: +1 415 660-5320
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 November 2026
Employees
357
Stocks News & Analysis
stocks
Sales shine but broader macro outlook darkens for this ASX share
US stores are struggling, but our investment thesis hinges on the Australian rollout.
stocks
Chart of the Week: US equity market trading at an attractive discount
The latest from our Chief US Market Strategist.
stocks
Undervalued ASX share retains wide moat rating despite regulatory pressures
Proposed price regulation impacts our fair value.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,168.90 | 43.80 | 0.48% |
| CAC 40 | 8,205.71 | 58.16 | -0.70% |
| DAX 40 | 23,744.10 | 336.53 | -1.40% |
| Dow JONES (US) | 47,769.34 | 140.58 | -0.29% |
| FTSE 100 | 10,583.05 | 25.83 | -0.24% |
| HKSE | 25,752.40 | 140.62 | -0.54% |
| NASDAQ | 22,595.00 | 39.99 | -0.18% |
| Nikkei 225 | 55,895.32 | 413.10 | -0.73% |
| NZX 50 Index | 13,273.81 | 19.87 | 0.15% |
| S&P 500 | 6,772.69 | 10.12 | -0.15% |
| S&P/ASX 200 | 8,973.20 | 57.80 | 0.65% |
| SSE Composite Index | 3,966.17 | 28.83 | -0.72% |